FluroTech

FluroTech Equity Growth

The Year-over-Year Equity Growth of FluroTech (TEST.H.V) as of Nov 2, 2026 is 8.76 %. In the previous year, Year-over-Year Equity Growth was -107.59 % — a change of -108.14% (higher).

Equity Growth

8.76 %

YoY

-108.14%

Last updated:

Year-over-Year Equity Growth of FluroTech is 2024 8.76 % . Year-over-Year Equity Growth of FluroTech was 2023 -107.59 % . It decreases by -108.14% higher compared to the previous year.

The FluroTech Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2017
-25.48 CAD
Jan 1, 2018
4,315.43 CAD
Jan 1, 2019
-46.59 CAD
Jan 1, 2020
-84.61 CAD
Jan 1, 2021
66.45 CAD
Jan 1, 2022
-111.15 CAD
Jan 1, 2023
-107.59 CAD
Jan 1, 2024
8.76 CAD
The FluroTech Equity Growth history
YEAREquity GrowthYoY
8.76 %-108.14%
-107.59 %-3.20%
-111.15 %-267.28%
66.45 %-178.53%
-84.61 %+81.58%
-46.59 %-101.08%
4,315.43 %-17,038.78%
-25.48 %+44.99%
-17.57 %-20.93%
-22.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

FluroTech Stock analysis

What does FluroTech do? FluroTech Ltd. commercializes fluorescence spectroscopy technology for pandemic defense through its subsidiary FluroTest Diagnostics Systems Ltd., which develops rapid antigen testing platforms for SARS-CoV-2 and other pathogens. The company targets high-traffic environments such as schools, hospitals, stadiums, and corporate campuses with its FluroTest system, utilizing robotics automation, biochemistry, fluorescence detection, and cloud computing to deliver results. FluroTest Diagnostics Systems Ltd. focuses on high-output rapid antigen testing for pandemic defense, serving sectors including healthcare, education, and public venues. The primary buyers of FluroTech's technology are institutions requiring rapid pathogen detection in high-traffic settings, including schools, colleges, hospitals, athletic venues, and corporate campuses. These organizations purchase the FluroTest system to manage pandemic risks through automated, high-volume testing solutions. The company's revenue streams are derived from the sale and deployment of its diagnostic platform across these institutional segments. FluroTech Ltd. leverages its subsidiary FluroTest Diagnostics Systems Ltd. to commercialize the PEDDP (pandemic and emerging disease defense platform), which is designed for environments like airports, cruise terminals, and shopping centers. The company's products are sold to entities needing rapid, scalable testing solutions for SARS-CoV-2 and other pathogens, with the focus on institutional rather than individual consumers. FluroTech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about FluroTech stock

Year-over-Year Equity Growth of FluroTech is 8.76 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth FluroTech since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's FluroTech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — FluroTech

All Key Metrics — FluroTech